ArticleFrontiers in medicine2026
Machine learning for biomarker-driven thalassemia diagnosis: a framework for causal effect estimation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia is one of the most heterogeneous diseases, with more than a thousand mutation types recorded worldwide. Molecular diagnosis of thalassemia by conventional PCR-based DNA analysis is time- and resource-consuming owing to the phenotype variability, disease complexity, and molecular diagnostic test limitations. Thalassemia diagnosis relies heavily on complex interactions among hematological biomarkers, making it challenging to distinguish causal relationships from mere statistical correlations. To address this limitation, this study proposes a causal machine learning framework that integrates causal discovery and counterfactual inference to identify biomarker-driven treatment effects for thalassemia diagnosis. The proposed approach models clinical variables using a Directed Acyclic Graph (DAG) to capture underlying causal dependencies and enables robust estimation of treatment effects while accounting for confounding factors. To address the primary objective from complementary causal perspectives, the framework combines adjusted regression for confounding control, inverse probability weighting for propensity-based estimation, Random Forest-based analysis for nonlinear feature importance and heterogeneous treatment effects, and bootstrap resampling for uncertainty quantification. The adjusted linear regression model yielded a conservative causal effect estimate of 0.3008, while propensity-based methods demonstrated stronger effects, with IPW producing an estimate of 1.0604. The bootstrap approach confirmed the stability of these findings with a 95% confidence interval of [0.8806, 1.2161], indicating statistically significant treatment influence. Furthermore, heterogeneous effect analysis using CATE revealed substantial variability across individuals, with estimates ranging between 0.0848 and 2.5200, highlighting the importance of personalized assessment. Stratified analysis across age groups showed distinct differences, with the highest effect observed in adolescents (1.3484) and lower effects in children (0.8856), emphasizing demographic-specific variations. The results demonstrate that key biomarkers, particularly hemoglobin-related features, exert significant causal influence on thalassemia diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.